Oncolytics Biotech (TSE:ONC) Sets New 12-Month Low – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$1.15 and last traded at C$1.17, with a volume of 121921 shares traded. The stock had previously closed at C$1.18.

Analysts Set New Price Targets

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The business has a 50 day simple moving average of C$1.51 and a 200-day simple moving average of C$1.41. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The stock has a market capitalization of C$90.69 million, a price-to-earnings ratio of -3.11 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.